Collagen Crosslinks, any Method — NCD 96 | CMS Coverage Update

TL;DR: The Centers for Medicare & Medicaid Services modified NCD 96 governing collagen crosslinks testing, effective March 7, 2026. Here's what billing teams need to know before submitting claims.

CMS collagen crosslinks coverage policy under NCD 96 has been updated. This National Coverage Determination governs Medicare coverage of bone resorption marker testing — the lab assays used to monitor osteoporosis treatment and assess bone turnover. The policy does not list specific CPT or HCPCS codes in this version's data, so your billing team should verify current applicable codes with your Medicare Administrative Contractor. The effective date of March 7, 2026 means claims submitted on or after that date must align with the updated criteria.

---

Quick-Reference Table

Field	Detail Copy
Payer	CMS (Centers for Medicare & Medicaid Services)
Policy	Collagen Crosslinks, any Method
Policy Code	NCD 96
Change Type	Modified
Effective Date	2026-03-07
Impact Level	Medium
Specialties Affected	Endocrinology, Rheumatology, Primary Care, Clinical Laboratory, Oncology
Key Action	Audit active osteoporosis patient claims against updated medical necessity criteria before March 7, 2026

---

CMS Collagen Crosslinks Coverage Criteria and Medical Necessity Requirements 2026

The core of this coverage policy is tightly scoped. CMS covers collagen crosslinks testing in specific clinical situations — and denies it in others. Knowing the line is the difference between clean claims and avoidable denials.

Collagen crosslinks are biochemical markers found in urine. Elevated levels signal elevated bone resorption. CMS recognizes that these markers provide useful adjunct diagnostic data when used alongside bone mass measurements — but the agency is explicit that the tests aren't appropriate for every Medicare patient with osteoporosis.

The policy outlines three covered indications:

#	Covered Indication Copy
1	Monitoring treatment response in patients with elevated bone resorption who have osteoporosis and are already on treatment.
2	Predicting response to FDA-approved antiresorptive therapy in postmenopausal women, as assessed by bone mass measurements.
3	Assessing response to treatment in patients with other conditions affecting bone — such as glucocorticoid-induced osteoporosis or cancer of the bone.

The testing method can be immunoassay or high performance liquid chromatography (HPLC). Both are covered when medical necessity criteria are met.

Here's the real issue with this policy: it's designed to limit use in patients for whom the test has no clinical value. CMS is blunt about this. Most "fast losers" of bone — the patients who would benefit most from this testing — reach age 65 already stabilized on therapy. By Medicare eligibility, the window of maximum clinical utility has often passed. Coverage exists primarily for younger Medicare beneficiaries, those on glucocorticoids, and those with secondary causes of bone loss.

If bone resorption is not elevated, repeat testing is not medically necessary. That sentence should be in bold on your charge capture checklist. CMS will deny repeat tests when the clinical rationale isn't there.

The policy also sets a reasonable measurement interval. Collagen crosslinks can show changes within three months of starting antiresorptive therapy — faster than bone mineral density measurements. That's clinically useful. But CMS requires that initial testing show elevated resorption before authorizing follow-up testing.

This policy does not explicitly require prior authorization at the national level. However, your Medicare Administrative Contractor may have a local coverage determination that adds prior auth or documentation requirements. Check with your MAC before assuming national coverage equals automatic approval.

---

CMS Collagen Crosslinks Exclusions and Non-Covered Indications

The exclusions here are as important as the covered indications. CMS built safeguards directly into NCD 96 to prevent excessive use.

Repeat testing when resorption is not elevated. If the initial test shows normal bone resorption, further testing is not covered. There's no ambiguity here. CMS states this directly: if bone resorption is not elevated, repeat testing is not medically necessary.

Routine screening without clinical indication. Collagen crosslinks testing is not a screening tool for the general Medicare population. Testing outside the three covered indications above will not meet medical necessity requirements and will be denied.

Patients for whom the test has no clinical relevance. CMS language specifically flags this. Patients who are well-stabilized on long-term therapy — and who would not have therapy changed based on results — do not meet medical necessity. The test has to have the potential to change clinical management to justify reimbursement.

The practical takeaway: collagen crosslinks billing requires documented clinical reasoning at every claim. The chart note has to show why this patient, at this time, meets one of the three covered indications. Vague osteoporosis diagnoses alone won't hold up.

---

Coverage Indications at a Glance

---

CMS Collagen Crosslinks Billing Guidelines and Action Items 2026

This policy update is a documentation problem as much as it is a coding problem. Your claims will stand or fall on the chart notes behind them. Here's what to do before and after the March 7, 2026 effective date.

Copy Action Items

---

CPT, HCPCS, and ICD-10 Codes for Collagen Crosslinks Testing Under NCD 96

Covered CPT and HCPCS Codes

This policy does not list specific CPT or HCPCS codes in the available policy data. This is common for NCDs, which set coverage criteria nationally but leave code-level specifics to Medicare Administrative Contractors through local coverage determinations.

Action required: Contact your MAC or check their LCD database to confirm the exact codes covered under NCD 96 in your jurisdiction. Submitting claims without confirming the applicable codes is the fastest route to a preventable denial.

Code	Type	Description Copy
Not specified in NCD 96 policy data	—	Verify with your MAC or LCD

Key ICD-10-CM Diagnosis Codes to Consider

While NCD 96 does not list ICD-10 codes explicitly, the covered indications point to the following diagnostic categories. Work with your compliance officer or billing consultant to confirm appropriate diagnosis code mapping for your MAC's LCD:

• Primary osteoporosis (postmenopausal, age-related)
• Secondary osteoporosis (glucocorticoid-induced, endocrine-related)
• Neoplasm of bone (where bone resorption monitoring applies)
• Pathological fracture risk conditions

Do not bill these without confirming they satisfy your MAC's specific LCD requirements. ICD-10 code selection here is not one-size-fits-all.

---